

CURRICULUM VITAE

July 2023

Afarin Rahimi-Movaghar, MD, MPH

Professor of Psychiatry,
Head, Iranian National Center for Addiction Studies (INCAS),
Tehran University of Medical Sciences

PERSONAL INFORMATION:

Date of birth: 18 Feb. 1966

Place of birth: Tabriz, IRAN

Marital status: Married (Husband: M.D., Urologist, Andrologist)

Nationality: Iranian

CONTACT ADDRESS:

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences,
Address: No. 486, South Karegar Ave., Tehran, Iran

Postal Code: 1336616357

Telefax.: -98-21-55421155

E-mail: rahimia@sina.tums.ac.ir**EDUCATION:**

1998-2001 Master's Degree in Public Health, Tehran University of Medical Sciences

1992 Board achievement of psychiatry (A degree), Tehran Institute of Psychiatry, Iran University of Medical Sciences

1983-1990 Graduation from Iran University of Medical Sciences (MD with A degree)

Short courses:

1995 Short-term Course of Research Methodology

1993 Short-term Course of Family Therapy

1992 Program of scholarship in EEG and EP in Princess Royal Hospital of England

POSITIONS IN IRAN:

2019-present	Head, Regional Capacity Building and Research Center for Treatment of Drug Use Disorders
2016-present	Professor, Tehran University of Medical Sciences
2015-present	Head, World Health Organization Collaborating Center on Research and Training on Mental Health and Substance Use
2015-2020	Chair, Working Group on Substance Use, Ministry of Health
2014-2015	Director, Center for Guideline Development on Addiction, Ministry of Health
2013-present	Lecturer, Ph.D. in Addiction Studies
2013-present	Director, Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences
2012-2014	Chair, National Committee for Planning on Substance Abuse Research, Drug Control Headquarters
2011-2015	Director, Office for Management of Research Centers, Tehran University of Medical Sciences
2009-2013	Director, Department for Drug Use and High-Risk Behaviors, Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences
2009-2012	Principal Investigator, Iranian Mental Health Survey
2009-2011	Head of the Team for "Priority setting for National Research Needs on Mental Health and substance abuse"
2009-2016	Associate Professor, Tehran University of Medical Sciences
2008-present	Member, Research Committee in "Mental Health Research Network"
2007-present	Founder and lecturer, MPH (Master of Public Health) with main emphasis on Drug Abuse
2007-2008	Member, Committee on Standards of Psychiatric Services, Ministry of Health
2007-2009	Member, National Committee on Mental Health, Ministry of Health
2006-2009	Member, Strategic Committee on Psychiatric Education, Ministry of Health
2006-2007	Director, Office for Mental Health, Ministry of Health
2005-2008	Director, Department for Mental Health Research, Psychiatric Research Center, Tehran University of Medical Sciences

July 2023

- 2005 Member, Planning Team for National Comprehensive Mental Health Programme
- 2003-present Lecturer, School of Public Health, Tehran University of Medical Sciences
- 2004-2009 Director, Department for Drug Abuse Epidemiology and Prevention, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences
- 2004-2005 Vice-chairman, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences
- 2004 Founder and Director, Iranian Databank of Drug Abuse Research
- 2004-2009 Assistant Professor, Tehran University of Medical Sciences
- 2004 Member of the Research Committee on Mental Health in Disasters, National Research Center for Medical Sciences, MOH
- 2003-2015 Founder and Director, Iranian Databank of Mental Health Research (IRANPSYCH)
- 2003-present Board Member, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences
- 2002-2005 Director, Department of Mental Health Research, National Research Center for Medical Sciences, MOH
- 2000-2008 Board Member, Iranian Scientific Society on Addiction
- 2000 Planning of the “First 5-year Programme on Drug Abuse Harm Reduction in Iran, Welfare Organization”
- 1999-2002 Membership of the joint committee of Iran and UNDCP on DDR (DARIUS Committee)
- 1998-2000 Membership of the “High Council Drug Abuse Prevention and Treatment in Ministry of Health”
- 1999 Member of the Planning Committee for “5-year Drug Demand Reduction Program”, Ministry of Health
- 1999 Head of the Committee for planning “5-year Drug Demand Reduction Program”, Drug Control Headquarters
- 1997-2005 Scientific cooperation with Mental Health Programs, Ministry of Health
- 1998 Head of the Planning Committee for Establishing “Pain Clinic in Iran Medical University”
- 1998-2002 Director, Office for Drug Abuse Prevention and Treatment, Social Welfare Organization, (First established in 1998)

July 2023

1998-2000	Membership of “The High Council Research and Planning in Drug Control Headquarters”
1996-2002	Planning and managing “Drug Abuse Treatment and Rehabilitation Programme in Iran”
1999-2002	Planning and managing the “Public Awareness Raising Programme on Drug Abuse in Iran”
1996-2002	Planning and managing “The First Comprehensive Community-based Drug Abuse Prevention Programme in Iran”
1996-1998	Responsible for Drug Abuse Prevention, Welfare Organization
1996-1998	Deputy Director, Office for Prevention of Social Pathologies, Social Welfare Organization
1993-1996	Teaching in Medical Collage at Azad University
1995-1996	Head of two Psychiatric Wards in Razi Hospital
1993-1996	Psychiatrist in Razi Psychiatric Center (The largest psychiatric hospital with 1000 beds in Iran)

INTERNATIONAL EXPERIENCES:

2022-present	Member, WHO Strategic and Technical Advisory Group on Mental Health, Brain Health, and Substance Use (STAG-MNS)
2023-present	ISAM (International Society for Addiction Medicine) Regional Representative for the region of Central Asia
2021-2022	Assessment of the situation and response to drug use and its harms in the Middle East and North Africa, supported by WHO
2021-present	Member, Guideline Development Group, WHO guideline on mhGAP
2020-present	Co-chair, Guideline Development Group, WHO guideline on ensuring balanced national policies for access and safe use of controlled medicines
2020-present	Editorial Board, Journal of Behavioral Addictions (IF 2021: 7.77)
2019-present	Associate Editor, Journal of Addiction (IF 2021: 7.26)
2019-2021	Member, Strategic and Technical Advisory Committee (STAC) for Global HIV, hepatitis and STI Programmes
2018-present	Co-chair, WHO Expert Committee on Drug Dependence (ECDD)

July 2023

2018-present	Member, Strategic Advisory Committee for World Drug Report, UNODC
2015-present	Member, WHO Expert Committee on Drug Dependence (ECDD)
2015-present	Member, WHO Technical Advisory Group on Alcohol and Drug Epidemiology
2014-2018	Member, Strategic Advisory Group to the United Nations on Injecting Drug Use and HIV
2011-2019	Member, WHO Working Group on the ICD-11 Classification of Substance-Related and Addictive Disorders
2009-2019	Member, WHO International Advisory Group for the Revision of ICD-10 Mental & Behavioural Disorders
2014	UNODC Consultant to review, for DO/DHB/HAS, country and regional data, estimation methodology, and HIV service coverage for World Drug Report
2009-2012	Member, UN Global Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users
2009	Member, WHO Technical Guideline Development Group (TDG) for Essential package for mental, neurological, and substance use disorders
2008-2015	Editorial Board, International Journal of Drug Policy (IF 2021: 5.93)
2020-Present	
2008	Consultant to review WHO, UNODC, and UNAIDS Technical Guide for countries to set targets for universal access to HIV prevention, treatment, and care for injecting drug users
2007-2009	Member, MENAHRA (Middle East and North African Harm Reduction Association) Project Management Group (PMG)
2007-2009	Responsible for Monitoring & Evaluation of the Project: Strengthening Civil Society's Role in Delivering Harm Reduction Services in the Middle East and North Africa (MENAHRA)
2005-2008	Member, WHO Technical Guideline Development Group (TDG) for Treatment of Opioid Dependence
2002-2009	Member, WHO/EMRO Regional Advisory Panel for Injecting Drug Use (RAPID)
2002-2006	Member of the UN Global Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users
2002	WHO Consultant on Review of Current Injecting Drug Use Problem in Oman
2002	WHO Temporary Adviser at the meeting on "Research for Change", Cape Town

- 2002 WHO consultant in “International Training Forum on Mental Health Policy Making and Service Development”, Tunis
- 2002 WHO Consultant, Strategic Planning for Drug Abuse in Jordan
- 2002 Short-Term Professional, Mental Health, DHP, WHO Eastern Mediterranean Regional Office (4 months)
- 2001-2006 Member, WHO Alcohol Policy Strategy Advisory Committee (APSAC)
- 2000 WHO Temporary Adviser at the meeting on HIV/AIDS and STD Surveillance, Lebanon
- 2000 WHO Temporary Adviser for the multisite project: “Urbanization, Adolescents and Risk Factors for Substance Abuse, Kobe, Japan
- 1999 Expert, Drug Demand Reduction, UNDCP Office, Tehran (6 months)

PUBLICATIONS:

ARTICLES IN PEER-REVIEWED JOURNALS:

1. Mohammad Aghaei A, Gholami J, Sangchooli A, Rostam-Abadi Y, Olamazadeh S, Ardeshir M, Baheshmat Sh, Shadloo B, Taj M, Saeed K, Rahimi-Movaghar A*. People who inject drugs in the Eastern Mediterranean Region, 2010-2022: Population size, characteristics, and prevalence of HIV, Hepatitis B, and C- A systematic review and meta-analysis. **The Lancet Global Health**, In Print.
2. Rostam-Abadi Y, Gholami J, Jobehdar MM, Ardeshir M, Aghaei AM, Olamazadeh S, Taj M, Saeed K, Mojtabei R, Rahimi-Movaghar A*. Drug use, drug use disorders, and treatment services in the Eastern Mediterranean region: a systematic review. **The Lancet Psychiatry**, 2023, 10(4): 282-295.
3. M. Filho A, Turner MC, Warnakulasuriya S, Richardson DB, Hosseini B, Kamangar F, Pourshams A, Sewram V, Cronin-Fenton D, Etemadi A, Glass DC. Rahimi-Movaghar A. ... The carcinogenicity of opium consumption: a systematic review and meta-analysis. **European Journal of Epidemiology**, 2023, 38(4): 373-89.
4. Rashidian H, Hadji M, Gholipour M, Naghibzadeh-Tahami A, Marzban M, Mohebbi E, Safari-Faramani R, Bakhshi M, Sadat Seyyedsalehi M, Hosseini B, Alizadeh-Navaei R, ... Rahimi-Movaghar A, Kamangar F, Zendehtdel K. Opium use and risk of lung cancer: A multicenter case-control study in Iran. **International Journal of Cancer**, 2023, 152(2): 203-13.

5. Noroozi A, [Rahimi-Movaghar A](#). Commentary on Nikoo et al.: Challenges in protocol development to optimize outcomes of opium tincture maintenance treatment. **Addiction**, 2023, 118(2): 295-6.
6. Ghani K, Farnam R, Rafiemanesh H, Shadloo B, Sangchooli A, Hamzehzadeh M, Mardaneh-Jobehdar M, Amin-Esmaeili M, Rahimi J, Demetrovics Z, Király O, [Rahimi-Movaghar A](#). Psychometric Properties of the Persian Version of the Gaming Motivation Scale (GAMS). **Psychiatry Investigation**, In Print.
7. Rafiemanesh A, Shadloo B, Amin-Esmaeili M, Rahimi J, Gholami J, [Rahimi-Movaghar A*](#). Prevalence of Tuberculosis in Iranian Drug Users: A Systematic Review and Meta-analysis. **Addiction and Health**, In Print.
8. Rafiemanesh H, Farnam R, Sangchooli A, Rahimi J, Hamzehzadeh M, Ghani K, Jobehdar MM, Amin-Esmaeili M, Shadloo B, Demetrovics Z, Király O., [Rahimi-Movaghar A*](#). Online gaming and internet gaming disorder in Iran: patterns, motivations, and correlates. **Current Psychology**, 2023, In Print.
9. Sangchooli A, Hamzehzadeh M, Rafiemanesh H, Ghani K, Farnam R, [Rahimi-Movaghar A](#). Development and psychometric evaluation of a DSM-V-based Social Networking Site Use Disorder Test: The SNS-DT-10. **Psychological Reports**, 2023, 126(3): 1551–1562.
10. Khave LJ, Noori M, [Rahimi-Movaghar A](#), Noroozi A. Management of gabapentin misuse in a patient with previous history of opioid use disorder: A case report. **Asian Journal of Psychiatry**, 2023, 80: 103322.
11. Khazaie H, Najafi F, Chehri A, [Rahimi-Movaghar A](#), Amin-Esmaeili M, Moradinazar M, Zakiei A, Pasdary Y, Brühl AB, Brand S, Sadeghi-Bahmani D. Physical activity patterns, circadian rhythms, and aggressive and suicidal behavior among a larger sample of the general population aged 15 to 34 years. **Journal of Clinical Medicine**, 2023, 12(8): 2821.
12. Rostam-Abadi Y, Amin-Esmaeili M, Baheshmat S, Mohammad Aghaei A, Gholami J, [Rahimi-Movaghar A](#). A six-year follow-up of people who use cannabis in Iran—a case series. **Addiction and Health**, 2023, 15(1): 71-6.
13. Aghaei AM, Gholami J, Amin-Esmaeili M, Baheshmat S, Rostam-Abadi Y, [Rahimi-Movaghar A](#). Six-year follow-up of people who use methamphetamine in Iran: a case series study. **International Journal of High Risk Behaviors and Addiction**, 2023,12(1): e131659.
14. Rafiemanesh H, [Rahimi-Movaghar A*](#), Shadloo B, Rostam-Abadi Y, Nedjat S, Yazdani K. Prevalence, pattern, and associated factors of alcohol use disorder among male treatment-seeking people with illicit drug use disorder in Tehran, Iran. **Journal of Substance Use**, 2023, 28(2): 211-6.
15. Amin-Esmaeili M, Shadloo B, [Rahimi-Movaghar A*](#), ... Major Depressive Disorder in Iran: Epidemiology, Health Care Provision, Utilization, and Challenges. **Archives of Iranian Medicine**, 2022, 25(5): 329-38.
16. Gholami J, Baheshmat S, Rostam-Abadi Y, Hamzehzadeh M, Mojtabai R, [Rahimi-Movaghar A*](#), Amin-Esmaeili M. Mortality and negative outcomes of opioid use and opioid use disorder: a six-year follow-up study. **Addiction**, 2022, 117(7): 2059–2066.

17. Baheshmat S, Gholami J, Amin-Esmaeili M, Shadloo B, [Rahimi-Movaghar A](#). Spouse and child abuse associated with illicit drug use in Iran: a systematic review and meta-analysis. **Trauma, Violence, & Abuse**, 2022, 23(5): 1494-509.
18. Carragher N, Billieux J, Bowden-Jones H, Achab S, Potenza MN, Rumpf HJ, Long J, Demetrovics Z, Gentile D, Hodgins D, Aricak OT, ... [Rahimi-Movaghar A](#), Brief overview of the WHO Collaborative Project on the Development of New International Screening and Diagnostic Instruments for Gaming Disorder and Gambling Disorder. **Addiction** (Abingdon, England), 2022, 117(7): 2119-2121.
19. Hadji M, Rashidian H, Marzban M, Naghibzadeh-Tahami A, Gholipour M, Mohebbi E, Safari R, Seyyedsalehi MS, Hosseini B, Bakhshi M, Alizadeh-Navaei R, ... [Rahimi-Movaghar A](#), Opium Use and Risk of Bladder Cancer: A Multicenter Case-Referent Study in Iran. **International Journal of Epidemiology**, 2022, 51(3): 830-838.
20. Rostam-Abadi Y, Gholami J, Noroozi A, Ansari M, Baheshmat S, Hamzehzadeh M, Ghadirzadeh MR, Vahdani B, Ekhtiari H, Mojtabei R, [Rahimi-Movaghar A*](#). Public health risks associated with methadone in Iran: A systematic review and meta-analysis. **International Journal of Drug Policy**, 2022, 100: 103529.
21. Hamzehzadeh M, Sangchooli A, Farnam R, Rafiemanesh H, Shadloo B, Ghani K, Jobehdar MM, Amin-Esmaeili M, Rahimi J, Demetrovics Z, Király O, [Rahimi-Movaghar A](#). Psychometric assessment of the Motives for Online Gaming Questionnaire among Iranian gamers. **Psychiatry Investigation**, 2022, 19(5): 333-40.
22. Gholami J, Rostam-Abadi Y, Rahimi J, Fotouhi A, Amin-Esmaeili M, [Rahimi-Movaghar A](#). HIV prevalence among non-injecting people who use drugs and related factors in Iran: A systematic review and meta-analysis. **Drug and Alcohol Review**, 2022, 41(3): 666-76.
23. Shadloo B, Baheshmat S, Rostam-Abadi Y, Shakeri A, Gholami J, [Rahimi-Movaghar A](#). Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder. **Journal of Substance Abuse Treatment**, 2022, 134: 108555.
24. Castro-Calvo J, King DL, Stein DJ, Brand M, Carmi L, Chamberlain SR, Demetrovics Z, Fineberg NA, Rumpf HJ, Yücel M, Achab S, ... [Rahimi-Movaghar A](#), Expert appraisal of criteria for assessing gaming disorder: An international Delphi study. **Addiction**, 2021, 116(9): 2463-75.
25. Rostam-Abadi Y, Gholami J, Amin-Esmaeili M, Baheshmat S, Hamzehzadeh M, Rafiemanesh H, Nasserbakht M, Ghalichi L, Safarcherati A, Taremiyan F, Mojtabei R, [Rahimi-Movaghar A*](#). Evidence for an increase in cannabis use in Iran—A systematic review and trend analysis. **PLOS One**, 2021, 16(8): e0256563.
26. Ansari M, Rostam-Abadi Y, Baheshmat S, Hamzehzadeh M, Gholami J, Mojtabei R, [Rahimi-Movaghar A*](#). Buprenorphine abuse and health risks in Iran: A systematic review. **Drug and Alcohol Dependence**, 2021, 226: 108871.
27. Ghanbari R, Li Y, Pathmasiri W, McRitchie S, Etemadi A, Pollock JD, Poustchi H, [Rahimi-Movaghar A](#), Amin-Esmaeili M, Roshandel G, Shayanrad A. Metabolomics reveals biomarkers of opioid use disorder. **Translational Psychiatry**, 2021, 11: 103. doi: 10.1038/s41398-021-01228-7.

28. Stone J, Degenhardt L, Grebely J, Larney S, Altice FL, Smyrnov P, [Rahimi-Movaghar A](#), Alavi M, Young AM, Havens JR, Miller WC. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. **Lancet Psychiatry**, 2021, 8(4): 301-309.
29. Khalili P, Nadimi AE, Baradaran HR, Janani L, [Rahimi-Movaghar A](#), Rajabi Z, Rahmani A, Hojati Z, Khalagi K, Motevalian SA. Validity of self-reported substance use: research setting versus primary health care setting. **Substance Abuse Treatment, Prevention, and Policy**, 2021, 16(66): <https://doi.org/10.1186/s13011-021-00398-3>.
30. Rafiemanesh H, [Rahimi-Movaghar A](#), Haghdoost AA, Noroozi A, Gholami J, Vahdani B, Afshar A, Salehi M, Etemad K. Opium dependence and the potential impact of changes in treatment coverage level: A dynamic modeling study. **Health Promotion Perspectives**, 2021, 11(2): 240-249.
31. Amin-Esmaeili M, Baheshmat S, Tarrahi MJ, Motevalian SA, Sharifi V, Hajebi A, Mojtabai R, [Rahimi-Movaghar A](#). Assessing risk behaviors in the Iranian general population: results from the Iranian Mental Health Survey. **Eastern Mediterranean Health Journal**, 2021, 27(10):953-61.
32. Mohebbi E, Rashidian H, Naghibzadeh Tahami A, Haghdoost AA, [Rahimi-Movaghar A](#), Seyyedsalehi MS, Rezaianzadeh A, Marzban M, Moradi A, Gholipour M, Hadji M. Opium use reporting error in case-control studies: neighborhood controls versus hospital visitor controls. **Medical Journal of The Islamic Republic of Iran (MJIRI)**, 2021, 35(1): 457-63.
33. Mohebbi E, Hadji M, Rashidian H, Rezaianzadeh A, Marzban M, Haghdoost AA, Naghibzadeh Tahami A, Moradi A, Gholipour M, Najafi F,... [Rahimi-Movaghar A](#), Opium use and the risk of head and neck squamous cell carcinoma. **International Journal of Cancer**, 2021, 148(5): 1066-76.
34. Hadji M, Rashidian H, Marzban M, Gholipour M, Naghibzadeh-Tahami A, Mohebbi E, Ebrahimi E, Hosseini B, Haghdoost AA, Rezaianzadeh A, [Rahimi-Movaghar A](#), et al. The Iranian Study of Opium and Cancer (IROPICAN): Rationale, design, and initial findings. **Archives of Iranian Medicine**, 2021, 24(3): 167-176.
35. Khazaie H, Najafi F, Hamzeh B, Chehri A, [Rahimi-Movaghar A](#), Amin-Esmaeili M, Moradi-Nazar M, Khazaie S, Zakiei A, Kamasi S, Pasdar Y. Cluster analysis of risky behaviors among the youth in Western Iran: Determining correlates and comparing clusters based on severity of disability and attitude toward mental health help-seeking. **Indian Journal of Psychiatry**, 2021, 63(5): 424-32.
36. Faghir Gangi M, Mirzazadeh A, Rastad H, Nejat S, [Rahimi-Movaghar A](#), Yazdani K. Reasons for not using condom by people who inject drugs in Iran; results from a conventional content analysis in 2018. **Iranian Journal of Epidemiology**, 2021, 17(3): 254-263. [Abstract in English, Full Text in Persian]
37. Warnakulasuriya S, Cronin-Fenton D, Jinot J, Kamangar F, Malekzadeh R, Dar NA, Etemadi A, Fortini P, Glass DC, Khanjani N, Kikura-Hanajiri R, Malats N, Pourshams A, [Rahimi-Movaghar A](#), et al. Carcinogenicity of opium consumption. **The Lancet Oncology**, 2020, 21(11):1407-8.

38. Rahimi J, Gholami Zh, Amin-Esmaeili M, Fotouhi A, Rafiemanesh H, Shadloo B, [Rahimi-Movaghar A*](#). HIV prevalence among People Who Inject Drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. **Addiction**, 2020, 115(4): 605-622.
39. Rostam-Abadi Y, Gholami J, Amin-Esmaeili M, Safarcherati A, Mojtabai R, Ghadirzadeh MR, Rahimi H, [Rahimi-Movaghar A](#). Tramadol use and public health consequences in Iran: a systematic review and meta-analysis. **Addiction**, 2020, 115(12): 2213-2242.
40. Rostam-Abadi Y, Rafiemanesh H, Gholami J, Shadloo B, Amin-Esmaeili M, [Rahimi-Movaghar A](#). Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis. **Harm Reduction Journal**, 2020, 17(1): 1-9.
41. Rafiemanesh H, Yazdani K, Nedjat S, Noroozi A, Saunders JB, Mojtabai R, [Rahimi-Movaghar A*](#). Alcohol Use Disorders Identification Test (AUDIT): Validation of the Persian version in an Iranian population. **Alcohol**, 2020, 83: 127-33.
42. Király O, Potenza MN, Stein DJ, King DL, Hodgins DC, Saunders JB, Griffiths MD, Gjoneska B, Billieux J, Brand M, Abbott MW, ... [Rahimi-Movaghar A](#), Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance. **Comprehensive Psychiatry**, 2020, 152180.
43. Ekhtiari H, Noroozi A, Farhoudian A, Radfar SR, Hajebi A, Sefatian S, Zare-bidoky M, Razaghi EM, Mokri A, [Rahimi-Movaghar A](#), Rawson R. The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity? **Addiction**, 2020, 115(7): 1395-403.
44. Wiens KE, Lindstedt PA, Blacker BF, Johnson KB, Baumann MM, Schaeffer LE, Abbastabar Sr H, Abd-Allah F, Abdelalim A, Abdollahpour I, Abegaz KH, ... [Rahimi-Movaghar A](#), Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17. **The Lancet Global Health**, 2020, 8(8): e1038-60.
45. Gangi MF, Karamouzian M, Nedjat S, [Rahimi-Movaghar A](#), Yazdani K, Shokoohi M, Mirzazadeh A. HIV prevention cascades for injection and sexual risk behaviors among HIV-negative people who inject drugs in Iran. **International Journal of Drug Policy**, 2020, 84: 102868.
46. Wang H, Abbas KM, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, Abolhassani H, Abreu LG, Abrigo MR, Abushouk AI, ... [Rahimi-Movaghar A](#), Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. **The Lancet**, 2020, 396(10258): 1160-203.
47. Murray CJ, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I, Abegaz KH, ... [Rahimi-Movaghar A](#), Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. **The Lancet**, 2020, 396(10258): 1223-49.
48. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, Abdollahi M, ... [Rahimi-Movaghar A](#), Global burden of 369 diseases and injuries

- in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. **The Lancet**, 2020, 396(10258): 1204-22.
49. Murray CJ, Abbafati C, Abbas KM, Abbasi M, Abbasi-Kangevari M, Abd-Allah F, Abdollahi M, Abedi P, Abedi A, Abolhassani H, Aboyans V, ... Rahimi-Movaghar A, Five insights from the global burden of disease study 2019. **The Lancet**, 2020, 396(10258): 1135-59.
 50. Faghir-Gangi M, Rastad H, Nejat S, Rahimi-Movaghar A, Yazdani K, Mirzazadeh A. Understanding the Reasons for Sharing Syringes or Needles to Inject Drugs: Conventional Content Analysis. **Addiction & Health**, 2020, 12(2): 98-108.
 51. Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BD, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, Larney S. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. **The Lancet**, 2019, 394(10208): 1560-79.
 52. Frank TD, Carter A, Jahagirdar D, Biehl MH, Douwes-Schultz D, Larson SL, Arora M, Dwyer-Lindgren L, Steuben KM, Abbastabar H, Abu-Raddad LJ, ... Rahimi-Movaghar A, Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. **The Lancet HIV**, 2019, 6(12): e831-59.
 53. Alavi M, Poustchi H, Merat S, Kaveh-ei S, Rahimi-Movaghar A, Shadloo B, Hajarizadeh B, Grebely J, Dore GJ, Malekzadeh R. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. **International Journal of Drug Policy**, 2019, 72: 99-105.
 54. Akbari H, Roshanpajouh M, Nourijelyani K, Mansournia MA, Rahimi-Movaghar A*, Yazdani K. Profile of drug users in the residential treatment centers of Tehran, Iran. **Health Promotion Perspectives**, 2019, 9(3): 248.
 55. Reed GM, First MB, Kogan CS, Hyman SE, Gureje O, Gaebel W, Maj M, Stein DJ, Maercker A, Tyrer P, Claudino A, ... Rahimi-Movaghar A, Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. **World Psychiatry**, 2019, 18(1): 3-19.
 56. Bastani P, Marshall BD, Rahimi-Movaghar A, Noroozi A. The risk environments of people who use drugs accessing two harm reduction centers in Tehran, Iran: A qualitative study. **International Journal of Drug Policy**, 2019, 63: 90-6.
 57. Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani OM, Ahmadnia S, Ahmadvand A, Arabi M, Ardalan A, Arhami M, Azizi MH, ... Rahimi-Movaghar A, Iran in transition. **The Lancet**, 2019, 393 (10184): 1984-2005.
 58. Shokoohi M, Rahimi-Movaghar A, Noroozi A, Karamouzian M. A public health approach to alcohol use and its related harms in Iran. **The Lancet Public Health**, 2019, 4(4): e175-6.

59. Naghavi M, ... [Rahimi-Movaghar A](#), Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. **British Medical journal (BMJ)**, 2019, 364: 194.
60. Rahman A, Hamoda HM, [Rahimi-Movaghar A](#), Khan M, Saeed K. Editorial: Mental health services for youth in the Eastern Mediterranean Region; challenges and opportunities. **Eastern Mediterranean Health Journal**, 2019, 25(2): 80-1.
61. Rumpf HJ, Brandt D, Demetrovics Z, Billieux J, Carragher N, Brand M, Bowden-Jones H, [Rahimi-Movaghar A](#), Assanangkornchai S, Glavak-Tkalic R, Borges G, et al. Epidemiological Challenges in the Study of Behavioral Addictions: a Call for High Standard Methodologies. **Current Addiction Reports**, 2019, 6(3): 331-337.
62. Mohebbi E, Kamangar F, [Rahimi-Movaghar A](#), Haghdoost AA, Etemadi A, Amirzadeh S, Najafi F, Shafeie F, Fakhari A, Ghalebani K, Shahid-Sales S. An exploratory study of units of reporting opium use in Iran: implications for epidemiologic studies. **Archives of Iranian Medicine**, 2019, 22(10): 541-5.
63. Khazaie H, Hamzeh B, Najafi F, Chehri A, [Rahimi-Movaghar A](#), Amin-Esmaeili M, Moradi-Nazar M, Zakiee A, Komasi S, Pasdar Y. Prevalence of Psychiatric Disorders and Associated Factors among the Youth in Ravansar, Iran. **Archives of Iranian Medicine**, 2019, 22(8): 435-42.
64. Niknamfar S, Zadeh-Tehrani SN, Sadat-Shirazi MS, Akbarabadi A, [Rahimi-Movaghar A](#), Zarrindast MR. μ -Opioid receptor in the CA1 involves in tramadol and morphine cross state-dependent memory. **Neuroscience Letters**, 2019, 705: 177-82.
65. Király O, Bóthe B, Ramos-Díaz J, [Rahimi-Movaghar A](#), Lukavska K, Hrabec O, Miovsky M, Billieux J, Deleuze J, Nuyens F, Karila L. Ten-Item Internet Gaming Disorder Test (IGDT-10): Measurement invariance and cross-cultural validation across seven language-based samples. **Psychology of Addictive Behaviors**, 2019, 33(1): 91-103.
66. Moradpour F, Hajebi A, Salehi M, Solaymani-Dodaran M, [Rahimi-Movaghar A](#), Sharifi V, Amin-Esmaeili M, Motevalian A. Province-level Prevalence of Psychiatric Disorders: Application of Small-Area Methodology to the Iranian Mental Health Survey (IranMHS). **Iranian Journal of Psychiatry**, 2019, 14(1): 16-32.
67. James SL, Theadom A, Ellenbogen RG, Bannick MS, Montjoy-Venning W, Lucchesi LR, Abbasi N, Abdulkader R, Abraha HN, Adsuar JC, Afarideh M, ... [Rahimi-Movaghar A](#), Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. **The Lancet Neurology**, 2019, 18(1): 56-87.
68. Marzban M, Hadji M, Gholipour M, Rashidian H, Rezaianzadeh A, Hasanzadeh J, Haghdoost AA, [Rahimi-Movaghar A](#), Ghiasvand R, Moradi A, Khavari-Daneshvar H, Weiderpass E, Kamangar F & Zendehdel K. Association of socioeconomic status with consumption of cigarettes, illicit drugs, and alcohol. **Journal of Ethnicity in Substance Abuse**, 2019, 18: 1-10.

69. Haddadi M, [Rahimi-Movaghar A](#), Farrahi F, Farahmandfar M. Comparison of the effects of methadone with buprenorphine on reproductive (sexual) hormone profile and seminal fluid analysis (fertility) in men on maintenance treatment. **Clinical Excellence**, 2019, 9(1): 48-60.
70. Safiri S, [Rahimi-Movaghar A](#), Mansournia MA, Yunesian M, Shamsipour M, Sadeghi-Bazargani H, Fotouhi A. Sensitivity of crosswise model to simplistic selection of nonsensitive questions: an application to estimate substance use, alcohol consumption and extramarital sex among Iranian college students. **Substance Use & Misuse**, 2019, 54(4): 601-11.
71. Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SR, Tymeson HD, Venkateswaran V, Tapp AD, Forouzanfar MH, Salama JS, Abate KH, ... [Rahimi-Movaghar A](#), Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. **The Lancet**, 2018, 392(10152): 1015-35.
72. Lozano R, Fullman N, Abate D, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdel-Rahman O, ... [Rahimi-Movaghar A](#), Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. **The Lancet**, 2018, 392(10159): 2091-138.
73. Stanaway JD, Afshin A, Gakidou E, Lim SS, Abate D, Abate KH, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, ... [Rahimi-Movaghar A](#), Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. **The Lancet**, 2018, 392(10159): 1923-94.
74. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdollahpour I, ... [Rahimi-Movaghar A](#), Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. **The Lancet**, 2018, 392(10159): 1859-922.
75. Dicker D, Nguyen G, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, ... [Rahimi-Movaghar A](#), Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. **The Lancet**, 2018, 392(10159): 1684-735.
76. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdollahpour I, ... [Rahimi-Movaghar A](#), ... Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. **The Lancet**, 2018, 392(10159): 1789-858.

77. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdollahpour I, ... [Rahimi-Movaghar A](#), ... Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. **The Lancet**, 2018, 392(10159): 1736-88.
78. Murray CJ, Callender CS, Kulikoff XR, Srinivasan V, Abate D, Abate KH, Abay SM, Abbasi N, Abbastabar H, Abdela J, Abdelalim A, ... [Rahimi-Movaghar A](#), ... Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. **The Lancet**, 2018, 392(10159): 1995-2051.
79. Khazaie H, Najafi F, Hamzeh B, Chehri A, [Rahimi-Movaghar A](#), Amin-Esmaeili M, Moradi-Nazar M, Zakiee A, Komasi S, Pasdary Y. Cluster analysis of psychiatric profile, its correlates, and using mental health services among the young people aged 15–34: findings from the first phase of Iranian youth cohort in Ravansar. **Social Psychiatry and Psychiatric Epidemiology**, 2018, 53(12): 1339-48.
80. Mansoori P, Majdzadeh R, Abdi Z, Rudan I, Chan KY, Aarabi M, Ahmadnezhad E, Ahmadnia S, Akhondzadeh S, Azin A, Azizi F, ... [Rahimi-Movaghar A](#), Setting research priorities to achieve long-term health targets in Iran. **Journal of Global Health**, 2018, 8(2).
81. [Rahimi-Movaghar A](#)*, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M. Pharmacological therapies for the management of opium withdrawal. **The Cochrane Database of Systematic Reviews**, 2018, 6: CD007522-.
82. Naghavi M, Marczak LB, Kutz M, Shackelford KA, Arora M, Miller-Petrie M, Aichour MT, Akseer N, Al-Raddadi RM, Alam K, Alghnam SA. ... [Rahimi-Movaghar A](#), ... Global mortality from firearms, 1990-2016. **JAMA**, 2018, 320(8): 792-814.
83. Amin-Esmaeili M, Motevalian A, [Rahimi-Movaghar A](#), Hajebi A, Sharifi V, Mojtabai R, Gudarzi SS. Bipolar features in major depressive disorder: Results from the Iranian mental health survey (IranMHS). **Journal of Affective Disorders**, 2018, 241: 319-24.
84. Hajebi A, Motevalian SA, [Rahimi-Movaghar A](#), Sharifi V, Amin-Esmaeili M, Radgoodarzi R, Hefazi M. Major anxiety disorders in Iran: prevalence, sociodemographic correlates and service utilization. **BMC Psychiatry**, 2018, 18(1): 261.
85. Abbasi-Ghahramanloo A, [Rahimi-Movaghar A](#), Zeraati H, Fotouhi A. Pattern of substance use among students of medical sciences in Tehran, Iran: A latent class analysis. **Journal of Substance Use**, 2018, 23(6): 648-54.
86. Amin-Esmaeili M, Motevalian A, Hajebi A, Sharifi V, Stockwell T, [Rahimi-Movaghar A](#)*. Methods for calculation of per capita alcohol consumption in a Muslim majority country with a very low drinking level: Findings from the 2011 Iranian mental health survey. **Drug and Alcohol Review**, 2018, 37: 874–878.
87. Shadloo B, Farnam R, Amin-Esmaeili M, Hamzehzadeh M, Rafiemanesh H, Jobehdar MM, Ghani K, Rahimi J, Sangchooli A, [Rahimi-Movaghar A](#)*. Ambiguities in existing Iranian national policies addressing excessive gaming: Commentary on: Policy responses to problematic video game use: A systematic review of current

- measures and future possibilities (Király et al., 2018). **Journal of Behavioral Addictions**, 2018, 7(3): 540–542.
88. Rumpf HJ, Achab S, Billieux J, Bowden-Jones H, Carragher N, Demetrovics Z, Higuchi S, King DL, Mann K, Potenza M, Saunders JB. ... Rahimi-Movaghar A, ... Including gaming disorder in the ICD-11: The need to do so from a clinical and public health perspective: Commentary on: A weak scientific basis for gaming disorder: Let us err on the side of caution (van Rooij et al., 2018). **Journal of Behavioral Addictions**, 2018, 7(3): 556–561.
 89. Fullman N, Yearwood J, Abay SM, Abbafati C, Abd-Allah F, Abdela J, Abdelalim A, Abebe Z, Abebo TA, Aboyans V, Abraha HN, ... Rahimi-Movaghar A, ... Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. **The Lancet**, 2018, 391(10136): 2236-71.
 90. Hajebi A, Motevalian A, Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hoseini L, Shadloo B, Mojtabai R. Adaptation and validation of short scales for assessment of psychological distress in Iran: The Persian K10 and K6. **International Journal of Methods in Psychiatric Research**, 2018, 27 (3): e1726.
 91. Khalili M, Rahimi-Movaghar A*, Shadloo B, Mojtabai R, Mann K, Amin-Esmaeili M. Global scientific production on illicit drug addiction: a two-decade analysis. **European Addiction Research**, 2018, 24: 60–70.
 92. Shadloo B, Amin-Esmaeili M, Motevalian A, Mohraz M, Sedaghat A, Gouya MM, Rahimi-Movaghar A. Psychiatric disorders among people living with HIV/AIDS in IRAN: Prevalence, severity, service utilization and unmet mental health needs. **Journal of Psychosomatic Research**, 2018, 110: 24-31.
 93. Motamedi MH, Abouie A, Hafezi-Nejad N, Saadat S, Rahimi-Movaghar A, Motevalian A, Masoumeh Ae, Sharifi V, Hajebi A, Ebrahimi A, Rahimi-Movaghar V. Prevalence and Costs of Complementary/Alternative Medicine among Traumatic Patients in Iran: A Nationwide Population-based Study. **Iranian Journal of Public Health**, 2018, 47(10): 1558-66.
 94. Noroozi A, Malekinejad M, Rahimi-Movaghar A. Factors influencing transition to shisheh (methamphetamine) among young people who use drugs in Tehran: a qualitative study. **Journal of Psychoactive Drugs**, 2018, 50 (3): 214-223.
 95. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar AA, Hekmatdoost A, Mohammadi Z, Mahmoudi Z, Shayanrad A, Roozafzai F, Sheikh M, Jalaiekhoo A, Hossein Somi M, Mansour-Ghanaei F, Najafi F, Bahramali E, Mehrparvar A, Ansari-Moghaddam A, Ali Enayati A, Esmaeili Nadimi A, Rezaianzadeh A, Saki N, Alipour F, Kelishadi R, Rahimi-Movaghar A, Aminisani N, Boffetta P, Malekzadeh R. Prospective epidemiological research studies in IrAN (The PERSIAN Cohort): rationale, objectives and design. **American Journal of Epidemiology**, 2018, 187(4): 647-655.
 96. Shokoohi M, Karamouzian M, Sharifi H, Rahimi-Movaghar A, Carrico AW, Hosseini-Hooshyar S, Mirzazadeh A. Crystal methamphetamine use and its correlates in women engaged in sex work in a developing country setting. **Drug and Alcohol Dependence**, 2018, 185: 260-265.

97. Khalagi K, Mansournia MA, Motevalian SA, Nourijelyani K, [Rahimi-Movaghar A](#), Bakhtiyari M. An ad hoc method for dual adjusting for measurement errors and nonresponse bias for estimating prevalence in survey data: Application to Iranian mental health survey on any illicit drug use. **Statistical Methods in Medical Research**, 2018, 27(10): 3062-3076.
98. Abouie A, Salamati P, Hafezi-Nejad N, [Rahimi-Movaghar A](#), Saadat S, Amin-Esmaeili M, Sharifi V, Hajebi A, Rahimi-Movaghar V. Incidence and cost of non-fatal burns in Iran: a nationwide population-based study. **International Journal of Injury Control and Safety Promotion**, 2018, DOI: 10.1080/17457300.2017.1310739.
99. Mokdad AH, Moradi-Lakeh M, Charara R, El Bcheraoui C, Khalil I, Afshin A, Kassebaum NJ, Collison M, Chew A, Krohn KJ, Daoud F, ... [Rahimi-Movaghar A](#), ... Intentional injuries in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study. **International Journal of Public Health**, 2018, 63 (Suppl 1): S39–S46.
100. Wang H, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Abraha HN, Abu-Raddad LJ, Abu-Rmeileh NM, Adedeji IA, ... [Rahimi-Movaghar A](#), ... Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. **The Lancet**, 2017, 390(10100): 1084-150.
101. Gakidou E, Afshin A, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulle AM, Abera SF, Aboyans V, Abu-Raddad LJ, Abu-Rmeileh NM, Abyu GY, ... [Rahimi-Movaghar A](#), ... Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. **The Lancet**, 2017, 390(10100): 1345-422.
102. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad LJ, ... [Rahimi-Movaghar A](#), ... Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. **The Lancet**, 2017, 390(10100): 1211-59.
103. Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad LJ, ... [Rahimi-Movaghar A](#), ... Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. **The Lancet**, 2017, 390(10100): 1260-344.
104. Amin-Esmaeili M, [Rahimi-Movaghar A*](#), Sharifi V, Hajebi A, Mojtabai R, Rad Goodarzi R, Hefazi M, Motevalian SA. Alcohol use disorders in Iran: prevalence, symptoms, correlates, and comorbidity. **Drug and Alcohol Dependence**, 2017, 176: 48–54.

105. Rashidian H, Hadji M, Marzban M, Gholipour M, [Rahimi-Movaghar A](#), Kamangar F, Malekzadeh R, Weiderpass E, Rezaianzadeh A, Moradi A, Babhadi-Ashar N. Sensitivity of self-reported opioid use in case-control studies: Healthy individuals versus hospitalized patients. **PLOS One**, 2017, 12(8): e0183017.
106. Shadloo B, Farnam R, Amin-Esmaeili M, Hamzehzadeh M, Rafiemanesh H, Jobehdar MM, Ghani K, Charkhgard N, [Rahimi-Movaghar A](#)*. Inclusion of gaming disorder in the diagnostic classifications and promotion of public health response: Commentary to the “Scholars’ open debate paper on the World Health Organization ICD-11 Gaming Disorder proposal”: A perspective from Iran. **Journal of Behavioral Addictions**, 2017, 6(3): 310-2.
107. Saunders JB, Hao W, Long J, King DL, Mann K, Fauth-Bühler M, Rumpf HJ, Bowden-Jones H, [Rahimi-Movaghar A](#), Chung T, Chan E. et al. Gaming disorder: Its delineation as an important condition for diagnosis, management, and prevention. **Journal of Behavioral Addictions**, 2017, 6(3): 271-9.
108. Rafiemanesh H, [Rahimi Movaghar A](#), Nedjat S, Noroozi A, Yazdani K. An Overview of the Tools and Screening Tests for Detection of Alcohol Disorders. **Iranian Journal of Epidemiology**, 2017, 13(2): 98-109. [Abstract in English, Full Text in Persian].
109. Karimi H, Soleyman-Jahi S, Hafezi-Nejad N, [Rahimi-Movaghar A](#), Amin-Esmaeili M, Sharifi V, Hajebi A, Saadat S, Akbari Sari A, Rahimi-Movaghar V. Direct and indirect costs of nonfatal road traffic injuries in Iran: A population-based study. **Traffic Injury Prevention**, 2017, 18(4): 393-397.
110. Ghiasvand F, [Rahimi-Movaghar A](#), Esteghamati A, Hasibi M, Zakerzadeh N, Abbasian L. Depression improvement among patients with HIV and endocrine dysfunction after hormone therapy. **Iranian Red Crescent Medical Journal**, 2017, 19(4): e42148.
111. [Rahimi-Movaghar A](#), Noroozi A, Page K, Mohraz M, McFarland W, Malekafzali H, Malekinejad M. Transition to and away from injecting drug use among young drug users in Tehran, Iran: A qualitative study. **Iranian Journal of Psychiatry and Behavioral Sciences**, 2017, 11(1): e4561. doi: 10.5812/ijpbs.4561.
112. Amin-Esmaeili M, Hefazi M, Rad Goodarzi R, Motevalian SA, Sharifi V, Hajebi A, [Rahimi-Movaghar A](#)*. Out-of-pocket cost of drug abuse consequences: results from Iranian National Mental Health Survey. **Eastern Mediterranean Health Journal**, 2017, 23(3): 150-160.
113. Hoseinie L, Gholami Zh, Shadloo B, Mokri A, Amin-Esmaeili M, [Rahimi-Movaghar A](#). Drop-out from a drug treatment clinic and associated reasons. **Eastern Mediterranean Health Journal**, 2017, 23(3): 173-181.
114. Shadloo B, Amin-Esmaeili M, Haft-Baradaran M, Noroozi A, Ghorban-Jahromi R, [Rahimi-Movaghar A](#)*. Use of amphetamine-type stimulants in the Islamic Republic of Iran, 2004–2015: a review. **Eastern Mediterranean Health Journal**, 2017, 23(3): 245-256.
115. Amin-Esmaeili M, Yunesian M, Sahimi-Izadian E, Moinolghorabaei M, [Rahimi-Movaghar A](#)*. The prevalence of illicit substance use among students of medical sciences in Tehran: results from four repeated surveys. **Journal of Child & Adolescent Substance Abuse**, 2017, 26(2): 152-161.

116. Karimian M, Motevalian A, Damghanian M, [Rahimi-Movaghar A](#), Sharifi V, Amin-Esmaeili M, Hajebi A. Explaining socioeconomic inequalities in illicit drug use disorders in Iran. **Medical Journal of The Islamic Republic of Iran** (MJIRI), 2017, 31(1): 728-34.
117. Amin-Esmaeili M, [Rahimi-Movaghar A*](#), Sharifi V, Hajebi A, Rad Goodarzi R, Mojtabai R, Hefazi M, Motevalian SA. Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization: results from the Iranian Mental Health Survey. **Addiction**, 2016, 111(8): 1836–1847.
118. Amin-Esmaeili M, [Rahimi-Movaghar A*](#), Gholamrezaei M, Razaghi EM. Profile of people who inject drugs in Tehran, Iran. **Acta Medica Iranica**, 2016, 54(12): 793-805.
119. Safiri S, [Rahimi-Movaghar A](#), Yunesian M, Sadeghi-Bazargani H, Shamsipour M, Mansournia MA, Fotouhi A. Sub-grouping of risky behaviors among the Iranian college students: a latent class analysis. **Neuropsychiatric Disease & Treatment**, 2016, 12: 1809–1816.
120. Abbasi-Ghahramanloo A, [Rahimi-Movaghar A*](#), Zeraati H, Safiri S, Fotouhi A. Prevalence of hookah smoking and its related factors among students of Tehran University of Medical Sciences, 2012 – 2013. **Iranian Journal of Psychiatry and Behavioral Sciences**, 2016, 10(2): e4551.
121. Khalagi K, Mansournia MA, [Rahimi-Movaghar A](#), Nourijelyani K, Amin-Esmaeili M, Hajebi A, Sharifi V, Radgoodarzi R, Hefazi M, Motevalian SA. Assessing measurement error in surveys by latent class analysis: application on self-reported illicit drug use in Iranian Mental Health Survey data. **Epidemiology and health**. 2016, 38: e2016013.
122. Emadi-Koochak H, Yazdi F, Abdolbaghi MH, Salehi MR, Shadloo B, [Rahimi-Movaghar A](#). Breaking HIV news to clients: SPIKES strategy in post-test counseling session. **Acta Medica Iranica**, 2016, 54(5): 313-7.
123. Safarcherati A, Amin-Esmaeili M, Shadloo B, Mohraz M, [Rahimi-Movaghar A](#). Correlation of mental illness and HIV/AIDS infection. **Tehran University Medical Journal (TUMJ)**, 2016, 73(10): 685-692.
124. Saadat S, Hafezi-Nejad N, Ekhtiari YS, [Rahimi-Movaghar A](#), Motevalian A, Amin-Esmaeili M, Sharifi V, Hajebi A, Radgoodarzi R, Hefazi M, Eslami V. Incidence of fall-related injuries in Iran: a population-based nationwide study. **Injury**, 2016, 47(7): 1404–1409.
125. Shooshtari MH, Malakouti SK, Panaghi L, Mohseni S, Mansouri N, [Rahimi-Movaghar A](#). Factors associated with suicidal attempts in Iran: a systematic review. **Iranian Journal of Psychiatry and Behavioral Sciences**, 2016, 10(1): e948.
126. Shadloo B, Motevalian A, [Rahimi-Movaghar A](#), Masoumeh AE, Sharifi V, Hajebi A, Radgoodarzi R, Hefazi M, [Rahimi-Movaghar A](#). Psychiatric disorders are associated with an increased risk of injuries: data from the Iranian Mental Health Survey (IranMHS). **Iranian Journal of Public Health**, 2016, 45(5): 623-35.
127. Malekinejad M, Navadeh S, Lotfizadeh A, [Rahimi-Movaghar A](#), Amin-Esmaeili M, & Noroozi A. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001–2012). **International Journal of Infectious Diseases**, 2015, 40: 116-130.

128. Motevalian A, Sadeghi R, Rahimi Movaghar A*, & Yunesian M. Age, period, and cohort effects on alcohol and drug use among students of Tehran University of Medical Sciences from 2006 to 2009. **Iranian Journal of Epidemiology**, 2015, 11(2): 99-108.
129. Rahimi-Movaghar A, Amin-Esmaeili M, Shadloo B, Noroozi A, & Malekinejad M. Transition to injecting drug use in Iran: a systematic review of qualitative and quantitative evidence. **International Journal of Drug Policy**, 2015, 26(9): 808-819.
130. Tarrahi MJ, Rahimi-Movaghar A*, Zeraati H, Amin-Esmaeili M, Motevalian A, Hajebi A, Sharifi V, Radgoodarzi R, Hefazi M, Fotouhi A. Latent class analysis of DSM-5 criteria for opioid use disorders: results from Iranian national survey on mental health. **European Addiction Research**, 2015, 21(3): 144-152.
131. Rahimi-Movaghar A, Amin-Esmaeili M, Safarcherati A, Sarami H, Rafiey H. A Scientometric Study of Iranian Scientific Productions in the Field of Substance Use and Addiction Research in the Years 2008 to 2012. **Addiction and Health**, 2015, 7(3-4): 99-108.
132. Yazdani K, Rahimi-Movaghar A, Nedjat S, Ghalichee L, Khalili M. Evaluation of the 5-Year Scientific Productions of the Research Centers Affiliated with Tehran University of Medical Sciences Using Scientometric Indicators and the Determinants. **Medical Journal of The Islamic Republic of Iran**, 2015, 29: 206.
133. Hafezi-Nejad N, Rahimi-Movaghar A, Motevalian A, Amin-Esmaeili M, Sharifi V, Hajebi A, Radgoodarzi R, Hefazi M, Eslami V, Karimi H, Saadat S, Mohammad K & Rahimi-Movaghar V. Population-based incidence and cost of non-fatal injuries in Iran: a consistent under-recognized public health concern. **Public Health**, 2015, 129: 483-492.
134. Malakouti SK, Nojomi M, Poshtmashadi M, Hakim Shooshtari M, Mansouri Moghadam F, Rahimi-Movaghar A, Bazargan-Hejazi S. Integrating a Suicide Prevention Program into the Primary Health Care Network: A Field Trial Study in Iran. **BioMed Research International**, 2015, 193729.
135. Abbasi-Ghahramanloo A, Fotouhi A, Zeraati H, Rahimi-Movaghar A*. Prescription drugs, alcohol, and illicit substance use and their correlates among students of medical sciences in Tehran, Iran. **International Journal of High Risk Behaviors and Addiction**, 2015, 4(1): e21945.
136. Sharifi V, Amin-Esmaeili M, Hajebi A, Motevalian SA, Rad Goodarzi R, Hefazi M, Rahimi-Movaghar A. Twelve-month prevalence and correlates of psychiatric disorders in Iran: The Iran Mental Health Survey, 2011. **Archives of Iranian Medicine**, 2015, 18(2): 76-84.
137. Salamati P, Rahimi-Movaghar A, Motevalian SA, Amin-Esmaeili M, Sharifi V, Hajebi A, et al. Incidence of self-reported interpersonal violence related physical injury in Iran. **Iranian Red Crescent Medical Journal**, 2015, 17(3): e15986.
138. Yazdani K, Nejat S, Rahimi-Movaghar A, Ghalichee L, Khalili M. Scientometrics: review of concepts, applications, and indicators. **Iranian Journal of Epidemiology**, 2015, 10: 78-88. [Abstract in English, Full Text in Persian].

139. Sadeghi M, Farhoudian A, Vishteh HRK, Rahimzadeh S, Fekri M, Rahimi-Movaghar A, & Sefatian S. A tentative component analysis of Norjizak: A new abused drug in Iran. **Pakistan Journal of Pharmaceutical Sciences**, 2015, 28(5): 1631-1636.
140. Hafezi-Nejad N, Rahimi-Movaghar A, Motevalian A, Amin-Esmaeili M, Sharifi V, Hajebi A, Radgoodarzi R, Hefazi M, Eslami V, Saadat S, Rahimi-Movaghar V. A nationwide population-based study on incidence and cost of non-fatal injuries in Iran. **Injury Prevention**, 2014, 20: e9.
141. Shamsipour M, Yunesian M, Fotouhi A, Jann B, Rahimi-Movaghar A, Asghari F, & Akhlaghi AA. Estimating the prevalence of illicit drug use among students using the crosswise model. **Substance Use & Misuse**, 2014, 49: 1303–1310.
142. Rahimi-Movaghar A, Amin-Esmaeili M, Sharifi V, Hajebi A, Hefazi M, Rad Goodarzi R, Motevalian S A. The Iranian Mental Health Survey: design and field procedures. **Iranian Journal of Psychiatry**, 2014, 9 (2): 96-109.
143. Amin-Esmaeili M, Motevalian A, Rahimi-Movaghar A*, Hajebi A, Hefazi M, Rad Goodarzi R, Sharifi V. Sheehan disability scale: translation and psychometric validation of the Persian version. **Iranian Journal of Psychiatry**, 2014, 9(3): 125-132.
144. Farhoudian A, Sadeghi M, Vishteh HRK, Moazen B, Fekri M, & Rahimi-Movaghar A. Component Analysis of Iranian Crack; A Newly Abused Narcotic Substance in Iran. **Iranian Journal of Pharmaceutical Research**, 2014, 13(1): 337-344.
145. Naserbakht M, Djalalinia S, Tayefi B, Gholami M, Ardabili ME, Shariat SV, Taban M, Hajebi A, Behtaj F, Sajadi SA, Rahimi-Movaghar A, Moradi M. & Farzadfar, F. National and sub-national prevalence, trend, and burden of mental disorders and substance abuse in Iran: 1990-2013, Study Protocol. **Archives of Iranian Medicine**, 2014, 17(3): 182 – 188.
146. Tarrahi MJ, Rahimi-Movaghar A*, Zeraati H, Amin-Esmaeili M, Motevalian A, Hajebi A, Sharifi V, Radgoodarzi R, Hefazi M, Fotouhi A. Agreement between DSM–IV and ICD–10 criteria for opioid use disorders in two Iranian samples. **Addictive Behaviors**, 2014, 39: 553-557.
147. Rahimi-Movaghar A, Amin-Esmaeili M, Hefazi M, Rafiey H, Shariat SV, Sharifi V, et. al. National priority setting for mental health in Iran. **Iranian Journal of Psychiatry and Clinical Psychology**, 2014, 20(3): 189-200 [Abstract in English, Full Text in Persian].
148. Sahebi R, Rahimi-Movaghar A, Motevalian A, Yunesian M. The Role of Age, Period, and Cohort Effects on Smoking among the Students of Tehran University of Medical Sciences. **European Online Journal of Natural and Social Sciences**, 2014, 3: 779-789.
149. Maleyrikhah Langroodi Z, Rahimi-Movaghar A*, Delbarpour Ahmadi S, Amin-Esmaeili M. Barriers of condom use among female sex workers in Tehran, a qualitative study. **Journal of School of Public Health and Institute of Public Health Research**, 2014, 12(2): 25-37 [Abstract in English, Full Text in Persian].

150. [Rahimi-Movaghar A*](#), Amin-Esmaeili M, Hefazi M, Yousefi-Nooraie R. Pharmacological therapies for maintenance treatments of opium dependence. **Cochrane Database of Systematic Reviews**, 2013, Issue 1.
151. Amin-Esmaeili M, [Rahimi-Movaghar A*](#), Yunesian M, Sahimi-Izadian E, & Moinolghorabaei M. Trend of smoking among students of Tehran University of Medical Sciences: results from four consecutive surveys from 2006 to 2009. **Medical Journal of the Islamic Republic of Iran**, 2013, 27(4): 168-178.
152. Amin-Esmaeili M, [Rahimi-Movaghar A*](#), Haghdoost AA, Mohraz M. Evidence of HIV epidemics among non-injecting drug users in Iran: a systematic review. **Addiction**, 2012, 107: 1929–1938.
153. Amin-Esmaeili M, [Rahimi-Movaghar A*](#), Razaghi EM, Baghestani A, Jafari S. Factors correlated with Hepatitis C and B virus infections among injecting drug users in Tehran, Iran. **Hepatitis Monthly**, 2012, 23-31. DOI: 10.5812/kowsar.1735143X.806.
154. Farhoudian A, [Rahimi-Movaghar A](#), Sefatian S, Mohammadi F. A Qualitative assessment of crack supply in Tehran, **Social Welfare Quarterly**, 2013, 12(4): 297-317 [Abstract in English, Full Text in Persian].
155. Hajebi A, Motevalian A, Amin-Esmaeili M, Hefazi M, Radgoodarzi R, [Rahimi-Movaghar A](#), Sharifi V. Telephone versus face-to-face administration of the Structured Clinical Interview for DSM-IV for diagnosis of psychotic disorders. **Comprehensive Psychiatry**, 2012, 53: 579–583.
156. [Rahimi-Movaghar A](#), Hefazi M, Amin-Esmaeili M, Sahimi-Izadian E, Yousefi-Nooraie R. Lifetime prevalence of tobacco use among high school students in Iran: a systematic review. **Payesh (Health Monitor)**, 2012, 11(3): 337-349. [Abstract in English, Full Text in Persian].
157. Sharifi V, Mesgarpour B, Basirnia A, Amin-Esmaeili M, Farhoudian A, Amini H, Mohammadi MR, [Rahimi Movaghar A](#), Salesian N, Yousefi-Nooraie R. Quality of studies on the prevalence of psychiatric disorders in Iran. **Iranian Journal of Psychiatry & Clinical Psychology**, 2012, 18(2): 138-149. [Abstract in English, Full Text in Persian].
158. Sharif-Alhoseini M, Saadat S, [Rahimi-Movaghar A](#), Motevalian A, Amin-Esmaeili M, Hefazi M, Rahimi-Movaghar V. Reliability of a patient survey assessing "Short Form Injury Questionnaire 7" in Iran. **Chinese Journal of Traumatology**, 2012, 15(3): 145-7.
159. [Rahimi-Movaghar A](#), Amin-Esmaeili M, Haghdoost AA, Sadeghirad B, Mohraz M. HIV prevalence among injecting drug users in Iran, a systematic review of studies conducted during a decade 1998-2007. **International Journal of Drug Policy**, 2012, 23: 271– 278.
160. Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, Ommeren M, Yasamy MT, Ayuso-Mateos JL, Birbeck GL, Drummond C, Freeman M, Giannakopoulos P, Levav I, Obot IS, Patel V, Phillips M, Prince M, [Rahimi-Movaghar A](#), et al. Evidence-based guidelines for mental, neurological, and substance use disorders in low and middle-income countries: Summary of WHO recommendations. **PLOS Medicine**, 2011, 8: e1001122. doi:10.1371/journal.pmed.1001122.

161. Hyman SE, Andrews G, Ayuso-Mateos JL, Gaebel W, Goldberg DP, Gureje O, Jablensky A, Khoury B, Lovell A, Medina Mora ME, Rahimi-Movaghar A, et al. A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders. **World Psychiatry**, 2011, 10: 86-92.
162. Shariat SV, Mansouri N, Gharaee B, Bolhari J, Yousefi Nooraie R, Rahimi-Movaghar A. Attitude, knowledge, and satisfaction of health personnel and the general population about the program of integration of mental health in PHC in Iran: Systematic Review. **Iranian Journal of Psychiatry & Clinical Psychology**, 2011, 17(2): 85-98. [Abstract in English, Full Text in Persian].
163. Rahimi-Movaghar A, Malayeri Langroodi Z, Delbarpoor Ahmadi Sh, Amin-Esmaeili M. A qualitative study of specific needs of women for the treatment of addiction. **Iranian Journal of Psychiatry & Clinical Psychology**, 2011, 17(2): 116-125. [Abstract in English, Full Text in Persian].
164. Rahimi-Movaghar A*, Khastoo G, Razzaghi E, Saberi-Zafarghandi MB, Noroozi AR, Jar-Siah R. Compulsory methadone maintenance treatment of severe cases of drug addiction in a residential setting in Tehran, Iran (2): Outcome evaluation in two and six-month follow-up. **Payesh (Health Monitor)**, 2011, 10: 503-512. [Abstract in English, Full Text in Persian].
165. Rahimi-Movaghar A*, Khastoo G, Razzaghi E, Saberi-Zafarghandi MB, Noroozi AR, Jar-Siah R. Compulsory methadone maintenance treatment of severe cases of drug addiction in a residential setting in Tehran, Iran (1): Process evaluation. **Payesh (Health Monitor)**, 2011, 10: 493-502. [Abstract in English, Full Text in Persian].
166. Rahimi-Movaghar A*, Khastoo G, Moinolghorabaei M, Yunesian M, Sadeghi AR. Use of stimulant substances among university students in Tehran: A Qualitative Study. **Iranian Journal of Psychiatry and Behavioral Sciences**, 2011, 5: 32-42.
167. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. **International Journal of Infectious Diseases**, 2010, 14: e28-33.
168. Sadeghirad B, Haghdoost AA, Amin-Esmaeili M, Shahsavand E, Ghaeli P, Rahimi-Movaghar A, Talebian E, Pourkhandani A, Noorbala AA, Barooti E. Epidemiology of major depressive disorder in Iran: a systematic review and meta-analysis. **International Journal of Preventive Medicine**, 2010, 1: 81-92.
169. Jafari S, Rahimi-Movaghar A, Craib K, Baharlou S, Mathias R. A follow-up study of drug users in Southern Iran. **Addiction Research & Theory**, 2010, 18: 59–70.
170. Shooshtari MH, Chimeh N, Najafi M, Mohammadi MR, Yousefi Nooraie R, Rahimi-Movaghar A. The prevalence of Attention Deficit Hyperactivity Disorder in Iran: A systematic review. **Iranian Journal of Psychiatry**, 2010, 5: 88-92.
171. Saberi-Zafarghandi MB, Rahimi-Movaghar A*, Hajebi A, Amin-Esmaeili M, Razaghi EM, Khastoo G, Jar-Siah R. Situation of drug use, addiction, and related services in the laborers of Assaluyeh industrial area (South Pars Gas Field) in 2007. **Hakim Research Journal**, 2010, 12(4): 58- 68 [Abstract in English, Full Text in Persian].

172. Mansouri N, Gharaee B, Shariat SV, Bolhari J, Yousefi Nooraie R, Rahimi-Movaghar A, Alirezaie N. The change in attitude and knowledge of health care personnel and general population following trainings provided during integration of mental health in Primary Health Care in Iran: a systematic review. **International Journal of Mental Health Systems**, 2009, 3:15.
173. Basirnia A, Sharifi V, Mansouri N, Mesgarpour B, Amin-Esmaeili M, Mohammadi MR, Amini H, Farhoudian A, Yousefi-Nooraie R, Rahimi Movaghar A. Prevalence of mental disorders among high-school students in Iran: A systematic review. **Iranian Journal of Psychiatry**, 2009, 4: 1-6.
174. Jafari S, Rahimi-Movaghar A, Craib K, Baharlou S, Mathias R. Socio-cultural factors associated with the initiation of opium use in Darab, Iran. **International Journal of Mental Health and Addiction**, 2009, 7: 376-388.
175. Amin-Esmaeili M, Nedjat S, Motevalian A, Rahimi-Movaghar A, Majdzadeh R. Comparison of databases for Iranian articles; Access to evidence on substance abuse and addiction. **Archives of Iranian Medicine**, 2009, 12: 559-565.
176. Mansouri N, Rahimi-Movaghar A, Sharifi V, Mohammadi M, Rad Goodarzi R, Sahimi Izadian E, Farhoudian A, Nejatisafa AA. Research on school mental health in Iran in the years 1973-2002. **Journal of Psychology and Education**, 2009, 38 (4): 1-20 [Abstract in English, Full Text in Persian].
177. Sharifi V, Rahimi-Movaghar A, Mohammadi M, Rad Goodarzi R, Sahimi Izadian E, Farhoudian A, Mansouri N, Nejatisafa AA. Analysis of mental health research in the Islamic Republic of Iran over 3 decades: a scientometric study. **Eastern Mediterranean Health Journal**. 2008, 14: 1060-1069.
178. Jafari S, Rahimi-Movaghar A, Baharlou S, Spittal P, Craib K. Trends of substance use in Southern Iran: A qualitative study. **Internet Journal of Epidemiology**, 2008, 6: No. 1.
179. Rahimi- Movaghar A*, Khastoo G, Fekri M, Akhondzadeh Sh. Treatment of addiction by medicinal herbs sellers in Tehran. **Hakim Research Journal**, 2008, 11(3): 11- 19 [Abstract in English, Full Text in Persian].
180. Malayeri Khah Langaroodi Z, Rahimi-Movaghar A, Yunesian M, Delbarpoor Ahmadi Sh, Shariati M. A study on social problems of wives of drug dependent men in a catchment area of Tehran. **Social Welfare Quarterly**, 2008, 7: 109-124 [Abstract in English, Full Text in Persian].
181. Cleland CM, Des Jarlais DC, Perlis TE, Stimson G, Poznyak V, and the WHO Phase II Drug Injection Collaborative Study Group (Including Rahimi-Movaghar A et al.). HIV risk behaviors among female IDUs in developing and transitional countries. **BMC Public Health**, 2007, 7: 271.
182. Farhoudian A, Amini H, Sharifi V, Basirnia A, Mesgarpour B, Mansouri N, Amin-Esmaeili M, Salesian N, Mohammadi MR, Yousefi-Nooraie R, Rahimi Movaghar A. Prevalence of psychiatric disorders in Iran: A systematic review. **Iranian Journal of Psychiatry**, 2007, 2: 137-149.
183. Amin-Esmaeili M, Rahimi-Movaghar A*, Sahimi-Izadian E, Hefazi M, Razaghi EM, Yousefi-Nooraie R. The prevalence of smoking among Iranian middle school students, a systematic review. **Iranian Journal of Psychiatry**, 2007, 2: 164-172.

184. Basirnia A, Sahimi-Izadian A, Arbabi M, Bayat Z, Vahid-Vahdat S, Noorbala A, Yousefi-Nooraie A, Rahimi-Movaghar A, Raisi F. Systematic review of prevalence of sexual disorders in Iran. **Iranian Journal of Psychiatry**, 2007, 2: 151-156.
185. Nejatisafa AA, Sahimi-Izadian E, Arbabi M, Vahid-Vahdat S, Molavi S, Rahimi-Movaghar A, Yousefi-Nooraie R. Prevalence of depression and anxiety in medical and surgical inpatients: a systematic review. **Iranian Journal of Psychiatry**, 2007, 2:181-185.
186. Gharraee B, Shariat SV, Mansouri N, Bolhari J, Yusefi Nourae R, Rahimi-Movaghar A. Case finding in integration of Mental Health Services into Primary Health Care System: systematic review of the studies conducted in Iran in recent two decades. **Iranian Journal of Psychiatry**, 2007, 2: 156-163.
187. Panaghi L, Malakouti S, Hakim Shoushtari M, Rahimi-Movaghar A, Mansouri N, Abarashi Z. Prevalence of self-inflicted burn and the related factors in Iran: A systematic review. **Iranian Journal of Psychiatry**, 2007, 2: 150-155.
188. Rahimi-Movaghar A. Towards evidence-based planning for research [Editorial]. **Iranian Journal of Psychiatry**, 2007, 2: 129-131.
189. Razzaghi EM, Rahimi-Movaghar A. Suicide prevention: A debate on interventions [Editorial]. **Iranian Journal of Psychiatry and Behavioral Sciences**, 2007, 1: 1-3.
190. Rahimi-Movaghar A, Farhoudian A, Rad Goodarzi R, Sharifi V, Yunesian M, Mohammadi M. Prevalence of drug use and its changes in the Bam survivors eight months after the Earthquake. **Payesh (Health Monitor)**, 2007, 6: 209-217 [Abstract in English, Full Text in Persian].
191. Farhoudian A, Rahimi-Movaghar A, Sharifi V, Mohammadi M, Rad Goodarzi R, Sahimi Izadian E, Mansouri N, Nejatisafa AA. A scientometric study on Iran's psychiatric research over three decades. **Iranian Journal of Psychiatry and Clinical Psychology**, 2007, 12: 327-336 [Abstract in English, Full Text in Persian].
192. Rahimi-Movaghar A, Farhoudian A, Rad Goodarzi R, Sharifi V, Yunesian M, Mohammadi M, A survey of changes in opioid use and risk factors in Bam earthquake survivors. **Tehran University Medical Journal**, 2006, 64: 77-94 [Abstract in English, Full Text in Persian].
193. Razzaghi EM, Rahimi-Movaghar A, Green TC, Khoshnood K, Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. **Harm Reduction Journal**, 2006, 3: 12.
194. Nejatisafa AA, Mohammadi M, Sharifi V, Rad Goodarzi R, Sahimi Izadian E, Farhoudian A, Mansouri N, Rahimi-Movaghar A. Iran's contribution to child and adolescent mental health research (1973-2002): A scientometric analysis. **Iranian Journal of Psychiatry**, 2006, 1: 93-97.
195. Rahimi-Movaghar A, Izadian E, Yunesian M. Drug use situation in university students in Iran: a literature review. **Payesh (Health Monitor)**, 2006, 5: 83-104 [Abstract in English, Full Text in Persian].

196. Farhoudian A, Sharifi V, Rahimi-Movaghar A, Rad Goodarzi R, Mohammadi M, Younesian M, Yasami MT. The prevalence of posttraumatic stress disorder and its symptoms among Bam earthquake survivors. **Advances in Cognitive Sciences**, 2006, 8: 56-70 [Abstract in English, Full Text in Persian].
197. Farhoudian A, Rahimi-Movaghar A, Rad Goodarzi R, Younesian M. Changes in the use of opioid drugs and available interventions in Bam during the first year after the Earthquake. **Hakim Research Journal**, 2006, 9: 52-57 [Abstract in English, Full Text in Persian].
198. Rad Goodarzi R, Rahimi-Movaghar A, Vazirian M. A Qualitative study of changes in supplying of illicit drugs in Bam during the first year after the earthquake. **Social Welfare Quarterly**, 2006, 5: 163-180 [Abstract in English, Full Text in Persian].
199. Sahimi Izadian E, Rad Goodarzi R, Rahimi-Movaghar A, Sharifi V, Mohammadi M, Farhoudian A, Mansouri N, Nejatisafa AA. Analysis of research on mental health in medical conditions in Iran. The **Tehran University of Medical Journal**, 2006, 63: 841-850 [Abstract in English, Full Text in Persian].
200. Rad Goodarzi R, Sharifi V, Rahimi-Movaghar A, Mohammadi M, Sahimi Izadian E, Farhoudian A, Mansouri N, Nejatisafa AA. Trend of Iran's mental health research over three decades. **Scientific Journal of School of Public Health, TUMS**, 2006, 4 (3): 1-14 [Abstract in English, Full Text in Persian].
201. Sahimi Izadian E, Rahimi-Movaghar A, Sharifi V, Mohammadi M, Rad Goodarzi R, Farhoudian A, Mansouri N, Nejatisafa AA. Status of mental health research concerning women in Iran over the past three decades, **Social Welfare Quarterly**, 2006, 5: 165-184 [Abstract in English, Full Text in Persian].
202. Rahimi-Movaghar A, Sharifi V, Mohammadi M, Rad Goodarzi R, Sahimi Izadian E, Farhoudian A, Mansouri N, Nejatisafa AA. Research on substance abuse in Iran; 3 decades evaluation. **Hakim Research Journal**, 2006, 8: 37-44 [Abstract in English, Full Text in Persian].
203. Rahimi-Movaghar A, Razzaghi EM. A qualitative study on opioid overdose in injecting drug users in Tehran. **Tehran University Medical Journal**, 2006, 64 (4): 43-53 [Abstract in English, Full Text in Persian].
204. Rahimi-Movaghar A, Izadian E. Drug use situation in school students in Iran. **Social Welfare Quarterly**, 2006, 5: 9-29 [Abstract in English, Full Text in Persian].
205. Rahimi-Movaghar A, Rad Goodarzi R, Izadian E, Mohammadi M, Hosseini M, Vazirian M. The impact of Bam earthquake on substance users in the first 2 weeks: a rapid assessment. **Journal of Urban Health**, 2005, 82: 370-377.
206. Rahimi Movaghar V, Rakhshani F, Mohammadi M, Rahimi-Movaghar A. Opioid use in patients with pain in Zahedan, Islamic Republic of Iran. **Eastern Mediterranean Health Journal**, 2004, 10: 82-89.
207. Rahimi-Movaghar A, Izadian E, Rad Goodarzi R, Mohammadi M. Rapid assessment of the attitudes of drug dependents and their relatives in Bam on the effects of drug dependency on losses and injuries caused by the earthquake. **Advances in Cognitive Sciences**, 2004, 5: 40-46 [Abstract in English, Full Text in Persian].
208. Rahimi-Movaghar A, Mohammadi M, Sahimi Izadian E, Sharifi V. Establishment of IranPsych database. **Social Welfare Quarterly**, 2004, 14: 259-264 [In Persian].

209. Rad Goodarzi R, [Rahimi-Movaghar A](#), Sahimi Izadian E, Mohammadi MR, Vazirian M. How did the health system deal with opioid withdrawal symptoms in Bam earthquake victims during the first two weeks after the disaster? **Journal of School of the Public Health, TUMS**, 2004, 3: 1-14 [Abstract in English, Full Text in Persian].
210. Sahimi Izadian E, [Rahimi-Movaghar A](#), Rad Goodarzi R, Mohammadi MR, Hosseini M. Withdrawal symptoms in drug dependents in Bam during the first two weeks after the earthquake. **Social Welfare Quarterly**, 2004, 13: 133-144 [Abstract in English, Full Text in Persian].
211. [Rahimi-Movaghar A](#), Nejatisafa AA, Mohammadi M, Sahimi Izadian E. A bibliometric study on mental health journals of Iran. **Andisheh Va Raftar (Journal of Mind and Behavior)**, 2004, 10: 28-36 [Abstract in English, Full Text in Persian].
212. [Rahimi-Movaghar A](#). A review of the prevalence and the patterns of drug abuse in women in Iran. **Social Welfare Quarterly**, 2004, 12: 203-226 [Abstract in English, Full Text in Persian].
213. Rahimi-Movaghar V, Rakhshani F, Mohammadi M, Sajadi A, [Rahimi-Movaghar A](#). Opioid use and related factors in patients with pain. **Tabib e Shargh**, 2003, 4: 171-180 [Abstract in English, Full Text in Persian].
214. Razzaghi EM, [Rahimi-Movaghar A](#), Mohammad K, Hosseini M. A qualitative study of risky sexual behavior of injecting drug users in Tehran. **Journal of School of the Health, TUMS**, 2003, 2(2): 1-10 [Abstract in English, Full Text in Persian].
215. [Rahimi-Movaghar A](#), Babaei N, Rostami M. A study of the prevalence rate of physical child abuse in two regions of Tehran. **Social Welfare Quarterly**, 2003, 2 (7): 141-160 [Abstract in English, Full Text in Persian].
216. [Rahimi-Movaghar A](#), Mohammad K, Razzaghi EM. Trend of drug abuse situation in Iran: a three-decade survey. **Hakim Research Journal**, 2002, 5 (3): 171-181 [Abstract in English, Full Text in Persian].

PRE-PRINTS:

- Boumparis N, Noroozi A, Naghizadeh E, Meyer A, Wenger A, Rahimi-Movaghar A, Schaub MP. Blended Smartphone Intervention for Patients in Opioid Maintenance Treatment in Iran: Protocol for a Randomized Controlled Trial. ResearchSquare, 2023.
- Ekhtiari H, Khojasteh Zonoozi A, ... [Rahimi-Movaghar A](#), et al. World Addiction Medicine Reports: Study Protocol for the International Society of Addiction Medicine (ISAM) Global Expert Network (ISAM-GEN) Surveys. PsyArXiv, 2022.
- Delavari S, Olamazadeh S, Baheshmat S, Gholami J, Shadloo B, Amin-Esmaeili M, [Rahimi-Movaghar A](#). Drug Use and its correlated factors among University students in Tehran. ResearchSquare, 2022.

BOOKS:

- Rahimi-Movaghar A, Amin-Esmaeili M, Shadloo B, Aaraj E. Assessment of situation and response of drug use and its harm in the Middle East and North Africa, 2017. Lebanon: Middle East and North Africa Harm Reduction Association (MENAHRRA) and Iranian National Center for Addiction Studies (INCAS), 2018.
- Amin-Esmaeili M, Shadloo B, Rahimi-Movaghar A. Identification and referral of at-risk populations (For HIV): a training manual for health-care workers. Tehran: Publication of Tehran University of Medical Sciences; 2014 [In Persian].
- Rahimi-Movaghar A, Amin-Esmaeili M, Sharifi V, et al. Iranian national mental health survey: prevalence, severity, and costs of mental disorders and service utilization (IranMHS). Tehran: Mehrsa publication; 2014 [In Persian].
- Rahimi-Movaghar A, Amin-Esmaeili M, Aaraj E, Hermez J. Assessment of situation and response of drug use and its harm in the Middle East and North Africa, 2012. Lebanon, Middle East and North Africa Harm Reduction Association (MENAHRRA), 2013.
- Rahimi-Movaghar A, Razzaghi EM, Haghdoost AA, Saberi-Zafarghandi MB, Bashti S, Mirzazadeh A, Safarcherati A, Noroozi AR, Roohparvar R, Mansouri N. The Geographical Distribution of Psychosocial Disorders and Substance use, Resources and Services in Iran, year 2005, Ministry of Health, Tehran, 2008.
- Shadloo B, Amin-Esmaeili M, Rahimi-Movaghar A. HIV testing and counseling: Textbook for HIV counselors. Tehran, Tehran University of Medical Sciences, 2013. [In Persian].
- Shadloo B, Amin-Esmaeili M, Rahimi-Movaghar A. HIV testing and counseling: Textbook for Physicians. Tehran, Tehran University of Medical Sciences, 2013. [In Persian].
- Amin-Esmaeili M, Inanlou M, Hefazi M, Rahimi Nejad F, Rahimi Movaghar A, et al. Practice guideline for Electro-Convulsive Therapy (ECT). Ministry of Health, Treatment and Medical Education Bureau for Mental and Social Health Mental Health office & Health Deputy of Kerman University of Medical Sciences, 2008. [In Persian].
- Hassanzadeh SM, Hajebi A, Hefazi M, Rahimi-Movaghar A, et al. Reporting of Suicide News on Media. Tehran, Zarnaghsh publication institute, 2008. [In Persian].
- Razzaghi EM, Rahimi-Movaghar A. Rapid Assessment and Response of Injection Drug Ues in Tehran, Final Report, WHO and Social Welfare Organization, Tehran, 2003.
- Razzaghi EM, Rahimi-Movaghar A, Hosseini M, Mohammad K, Madani S. Rapid situation assessment of drug abuse in Iran (2 Volumes), Social Welfare Organization and UNDCP, 2003 [In Persian].
- Kavian M, Lavasani F, Rahimi-Movaghar A, Hosseini M. Guidelines for prevention and treatment of substance dependence for mass media directors. State Welfare Organization, 2002 [In Persian].
- Rahimi-Movaghar A et al. Practical guidelines for drug abuse treatment. Ministry of Health, 2001 [In Persian].

Razzaghi EM, Khajavi M, Rahimi-Movaghar A, Hosseini M, Feizzadeh G. Prevention and treatment of substance dependence for community health workers. State Welfare Organization, 1998 [In Persian].

Rahimi-Movaghar A, Razzaghi EM, Khajavi M, Hosseini M, Feizzadeh G. Guidelines for prevention and treatment of substance dependence for four levels of health care system. State Welfare Organization, 1997 [In Persian].

Rahimi-Movaghar A et al. Persian Translation of “Rehabilitation of chronic mental disorders”, Comprehensive Textbook of Psychiatry. Kaplan and Sadock, 1995.

BOOK CHAPTERS:

Rahimi-Movaghar, A. Drug addiction. In Azizi F. (Ed.), Textbook of epidemiology and control of common diseases in Iran. Fourth Edition. Tehran: Shahid Beheshti University of Medical Sciences, 2016 [In Persian].

Rahimi-Movaghar, A. & Vameghi, M. Drug addiction. In S. Madani (Ed.), Social situation report of Iran. Tehran: Rahman Institute, 2011 [In Persian].

Tolan P, Schoeny M, Slavick J, Boonmongkon P, Czemy V, Eisenstein E, Rahimi-Movaghar A, et al. Chapter 11: Substance use among adolescents in urban areas: a brief survey in nine countries. In the book: Obot, IS, Saxena S, Substance use among young people in urban environments, World Health Organization, 2005.

TECHNICAL PUBLISHED REPORTS:

World Health Organization. WHO Expert Committee on Drug Dependence: forty-fifth report. Geneva: World Health Organization, 2023. WHO technical report series, No. 1046.

World Health Organization. WHO Expert Committee on Drug Dependence: forty-fourth report. Geneva: World Health Organization, 2022. WHO technical report series, No. 1038.

United Nations Office on Drugs and Crime, World Drug Report 2022. Vienna, United Nations publication, 2022.

World Health Organization. WHO Expert Committee on Drug Dependence: forty-third report. Geneva: World Health Organization, 2021. WHO technical report series, No. 1034.

United Nations Office on Drugs and Crime, World Drug Report 2021. Vienna, United Nations publication, 2021.

Working Group Members. IARC monographs on the identification of carcinogenic hazards to humans, Volume 126: Opium Consumption. Lyon: International Agency for Research on Cancer, 2021.

World Health Organization. WHO Expert Committee on Drug Dependence: forty-second report. Geneva: World Health Organization, 2020. WHO technical report series, No. 1026.

United Nations Office on Drugs and Crime, World Drug Report 2020. Vienna, United Nations publication, 2020.

- World Health Organization. WHO Expert Committee on Drug Dependence: forty-first report. Geneva: World Health Organization, 2019. WHO technical report series, No. 1018.
- United Nations Office on Drugs and Crime, World Drug Report 2019. Vienna, United Nations publication, 2019.
- World Health Organization. WHO Expert Committee on Drug Dependence: fortieth report. Geneva: World Health Organization, 2018. WHO technical report series, No. 1013.
- World Health Organization. WHO Expert Committee on Drug Dependence: thirty-ninth report. Geneva: World Health Organization, 2018. WHO technical report series, No. 1009.
- World Health Organization. WHO Expert Committee on Drug Dependence: thirty-eighth report. Geneva: World Health Organization, 2017. WHO technical report series, No. 1005.
- World Health Organization. WHO Expert Committee on Drug Dependence: thirty-seventh report. Geneva: World Health Organization, 2016. WHO technical report series, No. 998.
- World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization, 2009.
- World Health Organization. mhGAP: Mental Health Gap Action Programme: scaling up care for mental, neurological and substance use disorders. World Health Organization, 2008.

OTHER PUBLICATIONS:

- Rahimi-Movaghar A, Hefazi M, Davoli M, Amato L, Amin-Esmaeili M, Sahimi-Izadian E, Yousefi-Nooraie R. Pharmacological therapies for management of opium withdrawal (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007522. DOI: 10.1002/14651858.CD007522.
- Rahimi-Movaghar A. Criminalization & medicalization. Newsletter, I.R.of Iran Drug Control Headquarters, 2000, 1, No. 5, 10-12.
- Bolhari J, Moghaddasi M, Rahimi-Movaghar A. Primary prevention of epilepsy. Office for Control of Diseases, MOH, 1999 [In Persian].

ORAL PRESENTATIONS IN INTERNATIONAL CONFERENCES:

- "Mental health and substance abuse", 7th World Health Summit Regional Meeting, Kish, 2019, Karabey S, Rahimi-Movaghar A, Adli M, Hajebi A, Klabbbers G. [Oral presentation]
- "Development of a Manual on Psychotherapy for Addiction to Gaming and Social Networking", 6th International Conference on Behavioral Addictions, Yokohama, 2019, Farnam R, Rahimi-Movaghar A, et al. [Oral presentation].

- "National Study of Opium and Cancer in Iran (IROPICAN): Study Protocol and Results of the Pilot Phase", World Cancer Congress, Kuala Lumpur, 2018, Published in Journal of Global Oncology, Hadji M, Marzban M, Gholipour M, Rashidian H, Naghibzadeh-Tahami A, AA Haghdoost, A Rezaianzadeh, A Rahimi-Movaghar, et al. [Oral presentation].
- "Do gaming motives mediate between psychiatric symptoms and problematic online gaming? A cross-cultural study", 5th International Conference on Behavioral Addictions, Cologne, 2018, Published in Journal of Behavioral Addictions, Kiraly O, Choi SW, Ramos-Diaz J, Guevara-Cordero C, Rahimi-Movaghar A, et al. [Oral presentation].
- "Ten-Item Internet Gaming Disorder Test (IGDT-10): Psychometric properties across seven language-based samples", 4th International Conference on Behavioral Addictions, Haifa, Published in Journal of Behavioral Addictions, 2017, Demetrovics Z, Bothe B, Ramos Diaz J, Rahimi-Movaghar A, et al. [Oral presentation].
- "Twelve-month prevalence of psychiatric disorders in Iran: Results from the Iranian Mental Health Survey", XVI World Congress of Psychiatry, Madrid, 2014, Rahimi-Movaghar A, Sharifi V, Amin-esmaeili M, Hajebi A, Motevalian SA, Radgoodarzi R, Hefazi M. [Oral presentation].
- "Harm Reduction in Iran", International HIV/AIDS Congress, Tehran, 2012, Rahimi-Movaghar A. [Invited Speaker].
- "Developing a training package and program for drug abuse prevention in male high school students of Tehran", 5th International Congress of Child and Adolescent Psychiatry, Tehran, 2012, Rahimi-Movaghar A, Mahmoudi M, Safarcherati A, Aminesmaeili M, Khastoo G, Hosseini M, Momtazi S. [Oral presentation].
- "What is Norgestic, the new coming fatal drug in Iran?" 12th Annual Meeting of International Society of Addiction Medicine (ISAM), Milan, 2010, Farhoudian A, Rahimi-Movaghar A, Mohammadi, Fekri M. [Oral presentation].
- "Priority and target setting for supporting the countries of the Middle East and North Africa (MENA) Region in harm reduction activities", IHRA's 20th International Conference, Bangkok, 2009, Rahimi-Movaghar A, Razaghi EM, Elie A, Abou Shroush M, Assouab F, Hermèz J, Klaus K, Lagrich I, Mohsenifar S, Stimson G, Verster A. [Oral presentation].
- "Patterns of sexual behaviors among injecting drug users in Tehran, Iran", IHRA's 20th International Conference, Bangkok, 2009, Rahimi-Movaghar A, Razaghi E, Amin-Esmaeili M, Izadian E. [Oral presentation].
- "High risk behaviors related to injection drug use (IDU) in Iran, and 8 year trend analysis", IHRA's 19th International Conference, Barcelona, 2008, Razaghi E, Rahimi-Movaghar A, Sahimi-Izadian E, Amin Esmaeili M. [Oral presentation].
- "An experience from Bam Earthquake: Getting or losing opportunities?", 17th International Conference on the Reduction of Drug Related Harm, Vancouver, 2006, Rahimi-Movaghar A, Rad-Goodarzi R, Izadian E, Mohammadi MR, Vazirian M. [Oral presentation].

July 2023

- "Can we avert disaster? Experiences, strategies and responses when the availability of opiates is interrupted by catastrophe", 17th International Conference on the Reduction of Drug Related Harm, Vancouver, 2006, Catania H, Rahimi-Movaghar A, Vazirian M, Kaplan K, Maxwell S. [Oral presentation].
- "Health system response to opioid withdrawal symptoms in Bam earthquake survivors", XIII World Congress of Psychiatry, Cairo, 2005, Rad-Goodarzi R, Rahimi-Movaghar A, Izadian E, Mohammadi MR, Vazirian M. [Oral presentation].
- "Mental health research in Iran in the last three decades", XIII World Congress of Psychiatry, Cairo, 2005, Rahimi-Movaghar A, Sharifi V, Mohammadi M, Sahimi Izadian E, Rad Goodarzi R, Farhoudian A, Nejatisafa AA, Mansouri N. [Oral presentation].
- "Research in substance abuse in Iran in the last three decades", ISAM (International Society of Addiction Medicine) VII Annual Meeting, Mar del Plata, 2005, Rahimi-Movaghar A, Rad Goodarzi R, Sahimi Izadian E, Farhoudian A. [Oral presentation].
- "The impact of Bam earthquake on substance users in the first two weeks, A rapid assessment", ISAM (International Society of Addiction Medicine) VII Annual Meeting, Mar del Plata, 2005, Rahimi-Movaghar A, Rad Goodarzi R, Sahimi Izadian E, Mohammadi MR. [Oral presentation].
- "Analysis of sampling methodology utilized at Tehran WHO-IDU-RAR: Selection of different districts based on drug use prevalence", 15th International Conference on the Reduction of Drug Related Harm, Melbourne, 2004, Razzaghi E, Rahimi-Movaghar A. [Oral presentation].
- "IDU in women in Tehran: An IDU-RAR-based analysis", 15th International Conference on the Reduction of Drug Related Harm, Melbourne, 2004, Rahimi-Movaghar A, Razzaghi E. [Oral presentation].
- "Assessment of shared injection equipment among IDUs in Tehran", 14th International Conference on the Reduction of Drug Related Harm, Chiangmai, 2003, Rahimi Movaghar A, Razzaghi EM, Hosseini M, Rezaei-Fard H. [Oral presentation].
- "The extent of IDU and related factors in Tehran", 14th International Conference on the Reduction of Drug Related Harm, Chiangmai, 2003, Razzaghi EM, Rahimi Movaghar A, Hosseini M, Rezaei-Fard H. [Oral presentation].